RXRX240920C5000
- 2.48
- -0.37-12.98%
Recursion Pharmaceuticals Newsroom
Exscientia Plc Backs Acquisition by Recursion Pharmaceuticals
Trending Industry Today: Arm Holdings Leads Losses In NVIDIA Portfolio Stocks
Trending Industry Today: Arm Holdings Leads Gains In NVIDIA Portfolio Stocks
How Is The Market Feeling About Recursion Pharmaceuticals?
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
Is Recursion Pharmaceuticals Stock a Buy?
Small Cap Stocks: Recursion Pharmaceuticals (RXRX) Applying AI and Strategic Partnerships
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
Earnings Release: Here's Why Analysts Cut Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target To US$11.57
Recursion Pharmaceuticals Insider Sold Shares Worth $343,000, According to a Recent SEC Filing
Strategic Merger and Financial Prospects Affirm Buy Rating for Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript
Express News | Recursion Pharmaceuticals Inc : Needham Cuts Target Price to $16 From $17
Express News | Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $16
Recursion Pharmaceuticals Analyst Ratings
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
Recursion Pharmaceuticals (RXRX) Receives a Hold From TD Cowen
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Recursion Pharmaceuticals, Inc. Merger